Intravenous Immunoglobulin Market Size Report, 2032

Intravenous Immunoglobulin Market - By Product (IGG, IGA, IGM, IGD, IGE), Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Myasthenia Gravis, MMN, ITP), Distribution Channel (Hospital, Specialty), Global Forecast, 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Intravenous immunoglobulin industry 360&ordm; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Product trends

2.1.4&nbsp;&nbsp;&nbsp; Application trends

2.1.5&nbsp;&nbsp;&nbsp; Distribution channel trends

Chapter 3&nbsp;&nbsp;&nbsp;Intravenous Immunoglobulin Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing prevalence of immunodeficiency disorders

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing geriatric population

3.2.1.3&nbsp;&nbsp;&nbsp;Growing advances in plasma collection, fractionation, and purification technologies

3.2.1.4&nbsp;&nbsp;&nbsp;Increasing healthcare expenditure for immunoglobulins

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of IVIG therapy

3.2.2.2&nbsp;&nbsp;&nbsp;Potential adverse effects and allergic reactions

3.2.2.3&nbsp;&nbsp;&nbsp;Scarcity of plasma donors

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By product

3.3.2&nbsp;&nbsp;&nbsp; By application

3.3.3&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Intravenous Immunoglobulin Market Size and Forecast, By Product (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by product

5.2&nbsp;&nbsp;&nbsp; IgG

5.3&nbsp;&nbsp;&nbsp; IgA

5.4&nbsp;&nbsp;&nbsp; IgM

5.5&nbsp;&nbsp;&nbsp; IgD

5.6&nbsp;&nbsp;&nbsp; IgE

Chapter 6&nbsp;&nbsp;&nbsp;Intravenous Immunoglobulin Market Size and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Hypogammaglobulinemia

6.3&nbsp;&nbsp;&nbsp; Chronic Inflammatory demyelinating polyneuropathy (CIDP)

6.4&nbsp;&nbsp;&nbsp; Immunodeficiency diseases

6.5&nbsp;&nbsp;&nbsp; Myasthenia gravis

6.6&nbsp;&nbsp;&nbsp; Multifocal motor neuropathy

6.7&nbsp;&nbsp;&nbsp; Idiopathic thrombocytopenic purpura (ITP)

6.8&nbsp;&nbsp;&nbsp; Inflammatory myopathies

6.9&nbsp;&nbsp;&nbsp; Specific antibody deficiency

6.10&nbsp;&nbsp;&nbsp; Guillain-Barre syndrome

6.11&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Intravenous Immunoglobulin Market Size and Forecast, By Distribution Channel (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

7.2&nbsp;&nbsp;&nbsp; Hospital pharmacy

7.3&nbsp;&nbsp;&nbsp; Specialty pharmacy

7.4&nbsp;&nbsp;&nbsp; Other distribution channels

Chapter 8&nbsp;&nbsp;&nbsp;Intravenous Immunoglobulin Market Size and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited.

9.2&nbsp;&nbsp;&nbsp; Grifols SA

9.3&nbsp;&nbsp;&nbsp; CSL Behring

9.4&nbsp;&nbsp;&nbsp; ADMA Biologics

9.5&nbsp;&nbsp;&nbsp; Octapharma AG

9.6&nbsp;&nbsp;&nbsp; Baxter International Inc.

9.7&nbsp;&nbsp;&nbsp; LFB Biotechnologies

9.8&nbsp;&nbsp;&nbsp; China Biologics Products Inc.

9.9&nbsp;&nbsp;&nbsp; Kedrion Biopharma

9.10&nbsp;&nbsp;&nbsp; Intas Pharmaceuticals 
&nbsp;

Intravenous Immunoglobulin Market

Customize This Report